OPK

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended June 30, 2003, for eXegenics Inc. (Note: The input metadata listed "OPKO HEALTH, INC.", but the filing text explicitly identifies the registrant as eXegenics Inc.). The company historically operated as a drug discovery firm but shifted strategy in 2002 to focus on clinical drug development or business combinations. As of the reporting date, the company is navigating an unsolicited tender offer from the Foundation Group and a proposed merger with AVI BioPharma, Inc.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Collapse: Revenue dropped to zero for the quarter ended June 30, 2003, compared to $222,000 in the prior year quarter. For the six-month period, revenue fell 98% to $13,000 from $556,000, as the company terminated substantially all research and licensing agreements.
• Expense Reduction: Research and Development (R&D) expenses decreased 97% to $32,000 for the quarter (from $1,254,000) and 93% to $163,000 for the six months (from $2,476,000) due to the termination of scientific programs.
• Increased G&A: General and Administrative expenses increased 47% to $1,513,000 for the quarter, driven primarily by a $430,000 increase in legal fees related to the unsolicited tender offer and the proposed AVI merger.
• Strategic Redirection Costs: The company incurred a net charge of $299,000 for the quarter and $447,000 for the six months related to severance, legal fees, and equipment write-downs associated with terminating programs, partially offset by reimbursements from Bristol-Myers Squibb.
• Liquidity Improvement: Cash and cash equivalents increased from $6,188,000 at year-end 2002 to $13,487,000 at June 30, 2003, largely due to the maturity of a $10,000,000 government agency debt security in February 2003.

Guidance, Outlook, and Risks

• Merger Activity: The Board unanimously approved a merger agreement with AVI BioPharma, Inc., recommending stockholders accept the offer. The transaction values eXegenics shares at roughly 110% of net cash expected as of August 31, 2003. Estimated transaction costs total approximately $4.4 million.
• Unsolicited Offer: The company is simultaneously defending against an unsolicited tender offer from the Foundation Group, which was raised to $0.51 per share. The Board recommends rejecting this offer.
• Litigation: A class action lawsuit ("Weiss Litigation") was filed in May 2003 alleging mismanagement and breach of fiduciary duties. The company intends to dismiss the suit but cannot predict the outcome or liability.
• Delisting Risk: The company failed to regain compliance with Nasdaq's minimum bid price requirement ($1.00) by July 21, 2003. Nasdaq granted an extension until October 20, 2003, to regain compliance. Failure to do so could result in delisting and impaired liquidity.
• Future Operations: Management does not expect to record revenue for the foreseeable future as research programs have been terminated. The company believes current cash reserves are sufficient to fund operations through June 30, 2004.

Investor Verification Checklist

• Merger Approval: Verify the status of the AVI BioPharma merger vote and whether the $9 million net cash covenant condition is met.
• Delisting Status: Confirm if the company regained the $1.00 minimum bid price by the October 20, 2003 deadline to avoid Nasdaq delisting.
• Litigation Outcome: Monitor the Delaware Court of Chancery's ruling on the motion to dismiss the Weiss Litigation.
• Transaction Costs: Track actual legal and transaction expenses against the estimated $4.4 million to ensure cash reserves remain sufficient.
• Preferred Stock Dividends: Review the impact of Series A convertible preferred stock dividends on the net loss attributable to common shareholders.